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Abstract  
Chemerin acting via its distinct G protein-coupled receptor CMKLR1 (ChemR23), is a novel 
adipokine, circulating levels of which are raised in inflammatory states. Chemerin shows 
strong correlation with various facets of the metabolic syndrome; these states are associated 
with an increased incidence of cardiovascular disease (CVD) and dysregulated angiogenesis. 
We therefore investigated the regulation of ChemR23 by pro-inflammatory cytokines and 
assessed the angiogenic potential of chemerin in human endothelial cells (EC). We have 
demonstrated the novel presence of ChemR23 in human ECs and its significant up-regulation 
(P<0.001) by pro-inflammatory cytokines, TNF-, IL-1 and IL-6. More importantly, 
chemerin was potently angiogenic, as assessed by conducting functional in-vitro angiogenic 
assays; chemerin also dose-dependently induced gelatinolytic (MMP-2 & MMP-9) activity of 
ECs (P<0.001). Furthermore, chemerin dose-dependently activated PI3K/Akt and MAPKs 
pathways (P<0.01), key angiogenic and cell survival cascades. Our data provide the first 
evidence of chemerin-induced endothelial angiogenesis and MMP production and activity.  
 
 
 
 
 
 
 
 
 
 
 
Introduction  
Dysregulated angiogenesis is the hallmark of cardiovascular diseases
 
(CVD), with obesity 
and metabolic syndrome (MS) being significant contributors to CVD [1]. The metabolic 
syndrome is associated with excessive accumulation of central body fat. Adipose tissue 
produces several hormones and cytokines termed ‘adipokines’ having widespread metabolic 
effects on vascular endothelium [2,3]. Adipokines also appear to play important roles in the 
pathogenesis of insulin resistance, diabetes, and atherosclerosis [4]. Moreover, modulation of 
neo-angiogeneic responses of adipokines has been convincingly demonstrated within adipose 
tissue, further establishing the link between MS and CVD [5].  
Chemerin is a recently discovered 16-kDa adipokine and chemoattractant protein that serves 
as a ligand for the G protein-coupled receptor, CMKLR1 (ChemR23), with a role in adaptive 
and innate immunity [6,7]. Furthermore, chemerin is elevated in obesity and shows strong 
correlation with various facets of the MS, including dyslipidaemia and hypertension; we have 
recently shown serum and adipose tissue chemerin levels to be increased in women with MS 
[8,9]. Others, have reported elevated levels of circulating chemerin in inflammatory states, 
such as subjects with rheumatoid arthritis who are reported to have increased CVD; 
inflammation being a key player in immune mediated atherosclerosis [10,11].  
 
Recently, the chemerin/ChemR23 system has been implicated in mediating cellular migration 
under inflammatory conditions [12], a prerequisite of endothelial angiogenesis. This is of 
interest, as
 
it is increasingly evident from the literature that adipokines
 
play a significant role 
in the induction of atherogenesis and
 
dysregulated angiogenesis [13,14]. However, no studies 
to date have described the presence of ChemR23 in human endothelial cells (ECs) and its role 
in endothelial angiogenesis. 
 
With the aforementioned, we sought to investigate the possible interplay
 
between 
chemerin/ChemR23 system and the human endothelium. In the present study, we found and 
report for the first
 
time the presence of ChemR23 in human ECs, and its regulation by pro-
inflammatory cytokines. More importantly, chemerin induced endothelial angiogenesis and 
induced multiple signalling cascades including MAPK and Akt pathways and activates 
endothelial gelatinases (MMP-2/9). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Materials and Methods 
Cell Culture and Treatments  
Human Microvascular Endothelial Cells (HMECs) were obtained from the Centre for Disease 
Control (CDC) in Atlanta, Georgia, USA. Briefly HMECs were cultured in MCDB medium 
(Sigma-Aldrich, Dorset, UK) as described previously [15].  
For ChemR23 protein expression studies, optimization experiments were carried out by 
treating serum-starved ECs with or without human recombinant TNF- (0-20ng/mL) (NBS 
biologicals, Cambridgeshire, UK), IL-1 (0-100ng/mL) (ABCAM, Cambridgeshire, UK) and 
IL-6 (0-100ng/mL) (NBS biologicals, UK) in time-dependent manner (1 – 24 hours). 
ChemR23 blocking peptide was purchased from Sigma, UK. 
RNA Isolation and Real-Time Quantitative Reverse Transcription Polymerase Chain 
Reaction 
Total cellular RNA was extracted using the RNeasy Mini Kit (Qiagen Ltd, UK) according to 
the manufacturer’s protocol, followed by reverse transcription into cDNA, by using 5IU/ 
RevertAid H Minus M-MuLV Reverse Transcriptase (Fermentas, York, UK) as described 
previously [15], as was Quantitative PCR [15]. 
Protocol conditions consisted of denaturation at 94 °C for 1 min, then 38 cycles of 94 °C for 
30 s, 60 °C for 45 s, and 72 °C for 30 s, followed by a 7 min extension at 72 °C.  
Gene  Forward primer Reverse primer Product size 
ChemR23 5’-CAACCTGGCAGTGGCAGATT-3 5’AGCAGGAAGACGCTGGTGAA-3 153 (bp) 
β-actin 5’-AAGAGAGGCATCCTCACCCT-3 5’-TACATGGCTGGGGTCTTGAA-3’ 216 (bp) 
Table-1. Primer sequences 
PCR products were analyzed using Blast-Nucleic-Acid-Database Searches, confirming the 
identity of our products 
 
MTS Proliferation Assay 
Cell proliferation was determined with CellTiter-96 AQueous One Solution Cell Proliferation 
Assay (MTS) kit (Promega, UK) according to the manufacturer’s instructions. Briefly, 
serum-starved cells were dose-dependently treated with human recombinant chemerin (0 - 30 
nM) (R and D systems, Abingdon, UK) for 4 - 72 hours. Following chemerin treatment, 20μl 
MTS reagent was added to 100μl of culture medium per well. The absorbance at 490 nm was 
recorded using an ELISA plate reader (EL800, Bio-Tek Instruments, Inc., Winooski, VT, 
USA). The percentage of the absorbance was calculated against untreated cells. 
In-Vitro Angiogenesis Assay 
Angiogenesis was assessed by studying the formation of capillary-like structures by ECs on a 
Matrigel (BD Biosciences, San Jose, CA, USA) as described previously [15]. Briefly, serum-
starved ECs were pre-treated with or without chemerin (0-30 nM) and VEGF (10ng/mL) for 
24hrs. Cells were then seeded onto Matrigel coated plates at a density of 4-5 × 10
3
cells/well 
and incubated at 37 °C for 4, 9 or 18 hours. Capillary tube formation images were captured 
with a digital microscope camera system (Olympus, Tokyo, Japan). Tube lengths were 
quantified using Image-Pro Plus software; the length of tubes in 3-4 randomly selected fields 
in each of the wells was measured with the untreated groups. 
Migration Assay 
EC migration assay was performed according to the BD BioCoat Angiogenesis System (BD 
Biosciences) protocol. The assay was performed using a modified Boyden chamber as 
described previously [15]. Briefly, trypsinised, EC suspension of 4.0 x 10
5
 cells/ml was 
prepared and 250 μl of which was into the transwell inserts, followed by addition of 750μl of 
starvation media to the lower chamber. ECs were labelled by incubating with 50 nM Calcein-
AM in HBSS, for 90 minutes. The cells were treated with chemerin (0-30 nM) for 4, 8, 12 
and 24 hours, VEGF served as a positive control. ECs were the fixed by 2% formaldehyde. 
The migrated cells were quantified by using fluorescence plate reader. 
Gelatin Zymography 
The gelatinolytic activity of secreted MMP-2 and MMP-9 in the conditioned media was 
measured by gelatin zymography as described previously [15]. White bands were observed 
following de-staining indicating gelatinolytic activity of the expressed MMPs and the band 
intensities were measured [Gel Pro image analysis (Gel Pro 4.5, Media Cybernetics, USA)].  
Western Blot Analysis 
For the analyses and regulation of ChemR23 protein, serum-starved ECs were treated with or 
without human recombinant TNF- (0-20ng/mL), IL-1 (0-100ng/mL) and IL-6 (0-100ng/mL) in 
a time-dependent (1 – 24 hours) manner. The protocol for protein lysates preparation and 
western-blot analysis was as previously described [15], using primary anti-ChemR23 
antibody (dilution 1:1000) (Santa Cruz biotechnology, Middlesex, UK), and secondary anti-
goat horseradish-peroxidase-conjugated Ig (1:2000) (Dako Ltd, Cambridge, UK).  
Membranes were also re-probed with the β-actin antibody (Cell Signalling Technology Inc., 
Beverly, MA, USA; 1 in 8,000 dilution) to determine equal protein loading. Likewise, for 
MAPK (ERK1/2 and p38 MAPK) and Akt activation, immunoblotting was carried out as 
described previously [15].  
Statistical analysis 
All of the data in the present study are expressed as mean ± SEM. Comparisons among 
groups were made by ANOVA (non-parametric). When significance (P < 0.05) was detected, 
a post hoc Dunns multiple-comparison test was performed [Graph Pad software (version 
4.0)]. 
 
 
Results 
ChemR23 Expression in Human Endothelium 
RT-PCR analysis revealed the presence of ChemR23 mRNA in both micro (HMECs) and 
macro-vascular human ECs (HUVECs and EA.hy926) (Fig. 1A). Western blotting, using 
specific chemerin receptor antibody, confirmed its expression in both these cell types as a 42 
kDa band (predicted molecular weight) (Fig. 1B). The specificity of which was further 
confirmed by employing a ChemR23 blocking peptide (data not shown). Additionally, 
immunocytochemical analysis established the presence and distribution of ChemR23 in ECs 
(Fig. 1C). 
Regulation of Endothelial ChemR23 by Proinflammatory Cytokines 
Studies have elucidated the involvement of ChemR23 in chemerin induced inflammatory 
response/chemotaxis and specific recruitment of antigen-presenting cells to inflammatory 
sites [10]. Moreover, since these states are marked with increased circulating pro-
inflammatory cytokines, we hypothesised that; TNF-, IL-1, and IL-6 may have a 
regulatory effect on ChemR23 expression in ECs. We incubated serum-starved ECs with 
dose-dependent TNF- (0-20 ng/mL), IL-1 (0-100 ng/mL) and IL-6 (0-100 ng/mL) for 
various time points (1-24 hours). TNF- significantly and dose-dependently increased 
ChemR23 protein levels at both 12 and 24 hours (Fig 1D; ChemR23; P<0.001). IL-1 
significantly and dose-dependently increased ChemR23 protein levels at 12 hours, with 
maximal response at 100ng/mL. However at 24 hours, a dose-dependent decrease in 
ChemR23 protein expression, with maximal response at 1ng/mL, was observed (Fig 1E; 
P<0.001). IL-6 like IL-1 induced a significant dose-dependent increase in ChemR23 protein 
expression at 12 hours with maximal response at 100ng/mL (Fig 1F; P<0.001).   
Chemerin Induced In-Vitro Angiogenesis  
Chemerin increases EC proliferation 
Proliferation assay was performed in a time-dependent manner (4-48 hours) with maximal 
response being noted at 24 hours (data not shown). Serum starved ECs were treated with 
dose-dependent chemerin (0-30nM) and VEGF (10ng/mL) (positive control). At 24 hours, a 
significant increase in proliferation was observed at 0.1nM and 1.0 nM of chemerin and 
VEGF treatments [Fig 2A; 1.77 fold - VEGF (P < 0.001), and 1.41 fold-chemerin (0.1 nM) 
(P < 0.01) compared to basal (untreated); n=6 experiments]. These were additionally 
confirmed by a colorimetric Alamar-blue proliferation assay (data not shown).  
Chemerin induced capillary tube formation and migration of ECs 
Endothelial migration and capillary tube formation, like EC proliferation, are critical steps in 
angiogenesis, we performed Matrigel based capillary-like
 
tube formation assay. Treatment 
with chemerin promoted angiogenesis, as evidenced by capillary-like tube formation, in a 
time (0-24 hours) and dose (0-30 nM) dependent manner. Quantitative analyses revealed a 
significant increase in tube length induced by chemerin at 24 hours (Fig-2B1/B2; P<0.001, 
compared to basal; n = 6 experiments).   
Serum-starved, calcein labelled ECs were subjected to migration assay, treated with dose-
dependent chemerin (0-30nM) and VEGF (positive control) for 4, 8 12, and 24 hours. 
Chemerin increased migration in a dose-dependent and time-dependent manner, with a 
maximal effect at 30 nM after 24 hours (Fig-2C1/C2; P<0.001 chemerin treated vs. basal); 
confirming the migratory potential of chemerin in ECs. VEGF used a positive control, also 
significantly increased endothelial migration. 
 
 
Chemerin induced MAPKinase and Akt Signalling 
p38 MAPKinase and ERK1/2 activition 
MAPK signalling pathways are involved in EC proliferation and specifically, p38 MAPK 
signalling has been documented to be critically involved in endothelial angiogenesis [16]. We 
investigated transient phosphorylation of p38 MAPK in EC lysates treated with both time (0-
30 minutes) and dose (0-30nM) dependent chemerin. Chemerin significantly increased p38 
MAPK phosphorylation, maximally at 15 minutes (Fig-3A1: 3-fold increase compared to 
controls P<0.001) and at 0.1 nM (Fig-3A2: 3-fold compared to controls P<0.001). 
Interestingly, higher doses of chemerin (10nM and 30nM) failed to induce any significant 
changes in p38 MAPK phosphorylation. 
ERK1/2 signalling pathways are also involved in endothelial proliferation. Interestingly, time-
dependent stimulation of ECs with chemerin induced a biphasic response in ERK1/2 
phosphorylation, with maximal response at 5min, followed by a decline at 10 min, and a 
significant increase at 15min (Fig-3B1: P<0.001). Additionally, chemerin (0.1 nM) 
significantly increased phosphorylated ERK1/2 (Fig-3B2: 6-fold compared to controls; 
P<0.01). However, higher doses of chemerin (10nM and 30nM) failed to induce any change 
in phosphorylation of ERK1/2. This dose specific mediated ERK1/2 phosphorylation is 
particularly mirrored in chemerin induced EC proliferation, perhaps due to the vital 
involvement of ERK1/2 in EC proliferation. Interestingly, chemerin had no effect on JNK 
activity (data not shown).  
Chemerin Induced Akt signalling  
As for the MAPK signalling cascades, the Akt pathway plays a critical role in angiogenesis 
[17]. In order to address whether chemerin activates this pathway in ECs, we treated serum 
starved cells with dose (0-30 nM) and time-dependent (0-30 minutes) chemerin. A significant 
increase in Akt phosphorylation was observed at 5 minutes (Fig-2C1: 4-fold compared to 
controls; P<0.001), which decreased at 10 minutes (Fig-2C1: 1.5-fold compared to controls; 
P<0.05). Interestingly, unlike MAPK pathways, chemerin also induced a significant dose-
dependent increase in Akt phosphorylation, with maximum response at 10nM (Fig-2C2: 4-
fold compared to controls; P<0.001). 
Chemerin- induced Gelatinolytic Activity in Human ECs 
The angiogenic potential of ECs is greatly enhanced by extra-cellular matrix degradation, 
where gelatinases MMP-2/-9 play vital roles. To assess their involvement in chemerin 
induced angiogenesis, we performed gelatin zymography with the condition media of the 
aforementioned proliferation, migration and capillary tube formation assay (data not shown). 
Chemerin dose-dependently increased both MMP-2 (Fig-4A; P<0.001 chemerin treated vs. 
Basal) and MMP-9 (Fig-4B; P<0.001 chemerin treated vs. Basal) gelatinolytic activity in 
ECs. 
 
 
 
 
 
 
 
 
 
 
 
 
Discussion 
We describe novel findings, of the presence and regulation of endothelial ChemR23 by pro-
inflammatory cytokines. More importantly, we report that chemerin,
 
whose circulating 
concentrations are altered in obesity and obesity-related
 
disorders, activates key survival and 
angiogenic signalling cascades like MAPK and Akt pathways. Additionally, we demonstrate 
for the first time chemerin induced functional angiogenesis in human ECs, by promoting 
migration and capillary tube formation; and activation of endothelial gelatinases (MMP-2/-9).  
Altered expression of chemokines and their receptors during inflammatory processes may 
modify the equilibrium between angiostatic and angiogenic processes resulting in 
dysregulated angiogenesis leading to the development of CVD [18]. Of interest, chemerin 
was reported to strongly correlate with components of metabolic syndrome and pivotal 
inflammatory markers of CVD like TNF-, IL-6 and CRP [19].  
Studies have previously shown that up-regulation of chemokine receptors results in 
amplification of immunological responses by making the cells more responsive to stimuli. 
Furthermore, cytokine mediated synergistic inflammatory cascades are enhanced by 
modulation of receptor expression for one cytokine by the other [20-22]. In our present study, 
we observed a significant up-regulation of the chemokine receptor ChemR23 protein 
expression by pro-inflammatory cytokines (TNF-, IL-1 and IL-6).  Hence, given the 
existing pro-inflammatory environment and raised circulating cytokines in metabolic 
syndrome, it is tempting to propose a critical role mediated by chemerin in these 
inflammatory states.  
At a functional level, we report chemerin induced activation of key angiogenic and cell 
survival cascades, namely the MAPKs and Akt pathways, in humans ECs. A significant 
finding in our study is the highly reproducible biphasic pattern of activation of ERK1/2 
occurring within 2 minutes, peaking at 5minutes, followed by a rapid decline at 10 minutes, 
and then a subsequent increase at 15 minutes. The precise explanation for this observation 
remains to be determined; however, similar findings in other GPCR models that trigger a 
biphasic feed into Ras/Raf/MEK/ERK cascade have been reported but are poorly understood 
[23]. The plausible pathways implicated in the biphasic response include MMP-mediated 
shedding of heparin-sensitive EGF receptor ligands, EGF receptor auto-phosphorylation, and 
MEK1 activity [23]. In this context, it is interesting to note our robust data on chemerin 
induced gelatinolytic activity (MMP-2/-9) in ECs. Alternatively, this time mediated 
termination and reappearance of signalling cascade may involve feedback loops, consisting of 
degradation, inactivation of proteins and differential protein trafficking [24]. Future studies 
are therefore required to study and elucidate these interesting chemerin induced effects on 
ERK1/2 and p38 MAPK pathways. 
In addition, the dose-dependent effects of ERK phosphorylation were mirrored by chemerin 
induced EC proliferation.  However, and of interest, unlike EC proliferation, both chemerin 
induced migration and capillary tube formation seemed to follow a dose-dependent response 
similar to Akt activation. Of note, activation of Akt kinase has been implicated in 
orchestrating a number of signalling pathways potentially involved in angiogenic processes 
and survival pathways [17]. 
Enhanced production of MMPs, in particular gelatinases (MMP-2/-9), is an early feature of 
vascular remodelling and dysregulated angiogenesis, contributing to endothelial barrier 
dysfunction [25,26]. Our observations of chemerin inducing functional angiogenesis, with 
concurrent increases in gelatinolytic activity, suggest a potential causal relationship between 
chemerin induced MMP activity and angiogenesis. However, future studies are required to 
elucidate the precise role of gelatinases in chemerin induced angiogenesis. 
 
In conclusion, we demonstrate for the first time, presence of ChemR23 and chemerin induced 
in-vitro angiogenesis in human ECs. Our findings also confirm that chemerin activates key 
survival and angiogenic pathways including MAPK and Akt kinases. Finally, our data add to 
the diverse effects
 
of chemerin, but more importantly reveal novel insights into the potential 
role(s) of chemerin in human EC angiogenesis. 
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Figure Legends 
Figure-1. Identification of Chemerin receptor, ChemR23, and its regulation by 
proinflammatory cytokines; TNF-α, IL-1, and IL-6 in ECs 
Using PCR, western blot and immunocytochemical studies, ChemR23 mRNA and protein 
expressions were identified in human ECs. Human umbilical vein endothelial cells 
(HUVECs) were isolated and cultured as previously described [15]. (A)/(B)  represent 
mRNA and protein expression levels of ChemR23 in HMECs, EA.hy926 and HUVECs using 
PCR and western blot analyses respectively. Figure (C) shows immunostaining of ChemR23 
protein in ECs. In the next set, serum starved HMECs were treated with TNF-α [0-20 
ng/mL], IL-1β [0-100 ng/mL] and IL-6 [0-100 ng/mL] for 12 and 24 hours. Protein 
expression levels of ChemR23 were measured by western blot analyses. Figures (D), (E) and 
(F) denote representative western-blot analysis of ChemR23 protein expression following 
TNF-α, IL-1β and IL-6 treatments respectively. ***P<0.001, **P<0.01 vs. basal, Results are 
means ± S.E.M n = 6 experiments per group. 
Figure-2. Chemerin induced proliferation, capillary tube formation and migration of ECs 
in vitro. 
MTS Proliferation Assay: - Serum starved HMECs were treated with/without chemerin [0–
30 nM] and VEGF [10ng/mL] (positive control) for 24 hours and EC proliferation was 
assessed by MTS assay (A). Results were expressed as percentage of cells in relation to basal 
(untreated) and represents the mean of triplicates. ***P<0.001, **P < 0.01, *P < 0.05 vs. 
control, n = 6 experiments per group.   
Capillary Tube Formation Assay: - Chemerin [0-30nM] induced capillary tube formation in 
HMECs, and VEGF [10ng/mL] was used as a positive control. Figure (B1) shows graphical 
representation of capillary tube length (expressed as a percentage difference relative to basal), 
and (B2) represent images of capillary tube formation. Results are means ± S.E.M, n = 6 
experiments. ***P < 0.001, **P < 0.01, *P < 0.05 vs. basal. 
EC Migration Assay: - Serum starved Calcein-AM labelled HMECs were treated with 
chemerin [0-30 nM] for 4, 8, 12 and 24 hours. VEGF [10ng/ml] was used as a positive 
control. Migrated cells were quantified using a fluorescence plate reader.  The migrated cells 
were expressed as the ratio of the fluorescence compared to the control. Figure (C1) shows 
graphical representation of migratory distance (expressed as a percentage difference relative 
to basal), and (C2) represent images of wound scratch assay. Results are means ± S.E.M., n = 
6 experiments. ***P < 0.001, **P < 0.01, *P < 0.05 vs. basal. 
Figure-3. Chemerin-induced activation of p38 MAPKinase, ERK1/2 and Akt signalling 
pathways. 
Serum starved HMECs were treated with chemerin [0.1nM] in a time (0-30 minutes) and 
dose-dependent manner [0-30nM chemerin for 10 minutes]. Using western-blot analysis, 
phosphorylation of p38 MAPKinase, ERK1/2 and Akt were measured in above protein lysates. 
Figures (A1), (B1) and (C1) represent time, (A2), (B2) and (C2) denote dose-dependent 
effects of chemerin on p38 MAPKinase, ERK1/2 and Akt protein phosphorylation 
respectively. The results were represented as a ratio of phosphorylated/total protein, 
expressed as fold changes over basal. Results are means ± SEM., n = 6 experiments. 
***P<0.001, **P < 0.01, *P < 0.05 vs. basal. 
Figure-4. Chemerin enhances MMP-2 and MMP-9 gelatinolytic activity in ECs  
Chemerin enhanced gelatinolytic activity of both MMP-2/-9, when the condition media of the 
aforementioned capillary tube formation assay was subjected to gelatine zymography. 
Figures(A) and (B) denotes representative zymograms and densitometric analysis of MMP-2 
and MMP-9 protein activity in conditioned media for 24hours respectively. Results are means 
± S.E.M of six independent experiments. n = 6 per group ***P<0.001, **P < 0.01, *P < 0.05 
vs. basal.  
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